Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab with Chemoradiation for Operable Esophageal Cancer
NCT01077999Phase 2Completed
- Sponsor
- University of Amsterdam
- Start
- Jan 2010
- Primary completion
- Feb 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of panitumumab in esophageal cancer and gastroesophageal junction cancer, sponsored by University of Amsterdam. Started Jan 2010; status: completed.
02
Drugs
panitumumab
03
Conditions
esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT01077999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01077999.